Study of the Effect of VX-770 on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation



Status:Archived
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:January 2011

Use our guide to learn which trials are right for you!

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of VX-770 on Lung Clearance Index in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 >90% Predicted


The purpose of this study is to evaluate the effect of VX-770 on lung clearance index (LCI)
in subjects aged 6 years and older with cystic fibrosis (CF) who have the G551D-CFTR
mutation on at least 1 allele.


Cystic Fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene. The encoded protein, CFTR, is an epithelial chloride ion channel
responsible for aiding in the regulation of salt and water absorption and secretion in
various tissues. Although the disease affects multiple organs, the leading cause of
mortality is the progressive loss of lung function. Obstruction of airways with thick
mucous, chronic bacterial infection of the airways, and inflammatory response are all
thought to play a role in causing lung damage. Through its function as a chloride channel,
CFTR is believed to be integral in epithelial ion and water transport and hence, maintaining
the normal hydration of lung secretions.

VX-770 is a potent and selective potentiator of wild-type, G551D, F508del, and R117H forms
of human CFTR. Based on in vitro studies and pharmacologic, pharmacokinetic (PK), and safety
profiles, VX-770 has been selected for clinical development as a possible treatment for
patients with CF.

Currently, limited objective measures are available to quantify lung function in CF patients
with mild lung disease. Lung clearance index (LCI) derived from inert gas multiple-breath
washout (MBW) testing hold considerable promise to evaluate early lung disease as studies
have detected abnormalities in a high percentage of CF patients with normal spirometry in
both infants and children.


We found this trial at
4
sites
Bettendorf, Iowa 52722
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Charlotte, North Carolina
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials